UB-312 Synuclein Vaccine Safe in Controls. Next Up: Parkinson's.
In the field's quest for disease-modifying treatments, two different α-synuclein vaccines and two antibodies look promising in preclinical studies, as well.
6448 RESULTS
Sort By:
In the field's quest for disease-modifying treatments, two different α-synuclein vaccines and two antibodies look promising in preclinical studies, as well.
With effective symptomatic treatments in hand, many Parkinson’s researchers have now set their sights on loftier goals...
At AD/PD, scientists presented small molecules that break up fibrils and antibodies that target pathogenic forms of α-synuclein or hinder spread in iPSCs and mice.
Reactive astrocytes spell trouble for synapses, while microglial transform from protective to destructive as disease progresses.
For a diagnostic test, specificity and sensitivity fall a little shy. Using two cut points might solve the problem.
Fast Plaque Clearance with Little ARIA? So Teases Trontinemab at AD/PD 2024 TauRx Parses Subgroups to Make the Case for Methylene Blue Derivative, Again Therapeutic Contenders Target Hard-to-Reach Pockets of Tau Mouse Models and Markers for Cerebral Amylo
In London, researchers claimed that a monomer is the minimal structure required for tau strains. On the other hand, the sky seems the limit for the number of Aβ strains that form in an individual brain.
Preclinical studies and early phase trials target microglial receptors CD33 and TREM2, and amyloid-stoking ASC specks.
A trio of studies report that missense variants in SORL1 that disrupt its trafficking or dimerization are highly likely to cause Alzheimer's disease in carriers, strengthening the case for SORL1 being a familial AD gene.
First papers from MoTrPAC initiative report myriad responses to endurance training in multiple organs in rats, including the brain and heart.
Increasingly, people must learn of their amyloid status and/or ApoE genotype in order to enter secondary prevention trials. At AAIC, researchers laid out their procedures to ethically break the news.
In some patients, the blood Aβ42/40 test fell too close to the cutoff for specialists to confidently diagnose AD. Comorbidities, drugs also complicate results. Two CSF tests are FDA-approved.
Two studies describe how small peptides that latch onto tau have an outsize impact on fibrillization of the protein. Both point to therapeutic strategies.
Two interference screens netted a thousand proteins that affect tau oligomerization. The affected pathways? Mitochondrial malfunction, and UFMylation.
Queen Sylvia of Sweden traveled to Gothenburg to welcome scientists to AD/PD. At the conference, the buzz was on about approaches to double levels of the lysosomal protein in FTD.